Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss

BMC Biotechnology

Volumn 14, Issue 1, 2014, Pages

  Holtz, Kathleen M ^a   Robinson, Pamela S ^a   Matthews, Erin E ^a   Hashimoto, Yoshifumi ^a   McPherson, Clifton E ^a   Khramtsov, Nikolai ^a   Reifler, Michael J ^a   Meghrous, Jamal ^a   Rhodes, David G ^a   Cox, Manon M ^a   Srivastava, Indresh K ^a  

^a Protein Sciences Corp   (United States)

Author keywords

Antigen; Cysteine; Hemagglutinin; Influenza; Potency; Protein cross linking; Protein stability; Vaccine

Indexed keywords

ANTIGENS; COVALENT BONDS; LOSS PREVENTION; PURIFICATION; RECOMBINANT PROTEINS; REDUCING AGENTS; SULFUR COMPOUNDS; VACCINES; VIRUSES;

CYSTEINE; HEMAGGLUTININ; INFLUENZA; POTENCY; PROTEIN CROSSLINKING; PROTEIN STABILITY;

AMINO ACIDS;

ALANINE; CYSTEINE; INFLUENZA VACCINE; RECOMBINANT HEMAGGLUTININ PROTEIN; RECOMBINANT PROTEIN; SERINE; UNCLASSIFIED DRUG; INFLUENZA VIRUS HEMAGGLUTININ;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; BACULOVIRIDAE; CONTROLLED STUDY; CYTOPLASM; DRUG POTENCY; HEMAGGLUTINATION INHIBITION; IMMUNIZATION; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN STRUCTURE; SEASONAL INFLUENZA; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; PROTEIN TERTIARY STRUCTURE; VIROLOGY;

ANIMALS; CYSTEINE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 84964314332     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/s12896-014-0111-y     Document Type: Article

References (46)

1. Fiore AE, Bridges CB, Cox NJ: Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009, 333:43-82.
2. Monto AS, Ohmit SE: Seasonal influenza vaccines: evolutions and future trends. Expert Rev Vaccines 2009, 8:383-389.
3. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A: Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infec Dis 2009, 200:841-848.
4. Brands R, Visser J, Medema J, Palache AM, v. Scharrenburg GJ: Influvac: a safe madin Darby canine kidney (MDCK) cell culture-based influenza vaccine. Dev Bio Stand 1999, 98:93-100.
5. Cox MM, Hashimoto Y: A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol 2011, 107(Suppl):S31-S41.
6. Cox MM: Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther 2008, 10:56-61.
7. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM: Evaluation of the safety, reactogenicity, and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to health adults 50-64 years of age. Vaccine 2011, 29:2272-2278.
8. Tamm LK: Hypothesis: spring-loaded boomerang mechanism of influenza hemagglutinin-mediated membrane fusion. Biochim Biophys Acta 2003, 1614:14-23.
9. Wilson IA, Skehel JJ, Wiley DC: Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 1981, 289:366-373.
10. Bullough PA, Hughson FM, Skehel JJ, Wiley DC: Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994, 371:37-43.
11. Skehel JJ, Wiley DC: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531-569.
12. Tatulian SA, Tamm LK: Secondary structure, orientation, oligomerization, and lipid interactions of the transmembrane domain of influenza hemagglutinin. Biochemistry 2000, 39:496-507.
13. Chang DK, Cheng SF, Kantchev EA, Lin CH, Liu YT: Membrane interaction and structure of the transmembrane domain of influenza hemagglutinin and its fusion peptide complex. BMC Biol 2008, 6:2.
14. Scolari S, Engel S, Krebs N, Plazzo AP, De Almeida RF, Prieto M, Veit M, Herrmann A: Lateral distribution of the transmembrane domain of influenza virus hemagglutinin revealed by time-resolved fluorescence imaging. J Biol Chem 2009, 284:15708-15716.
15. Markovic I, Leikina E, Zhukovsky M, Zimmerberg J, Chernomordik LV: Synchronized activation and refolding of influenza hemagglutinin in multimeric fusion machines. J Cell Biol 2001, 155:833-844.
16. Palese P: Making better influenza virus vaccines? Emerg Infect Dis 2006, 12:61-65.
17. WHO: Recommendations for the production and control of influenza vaccine (inactivated). [http://www.who.int/biologicals/vaccines/influenza/en/]
18. Matthews JT: Egg-based production of influenza vaccine: 30 years of commercial experience. The Bridge: Linking Eng Soc 2006, 36:17-24.
19. Williams MS: Single-radial-immuno-diffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol 1993, 37:253-262.
20. Williams MS, Mayner RE, Daniel NJ, Phelan MA, Rastogi SC, Bozeman FM, Ennis FA: New developments in the measurement of the hemagglutinin content of influenza virus vaccines by single-radial-immunodiffusion. J Biol Stand 1980, 8:289-296.
21. Hickey JM, Holtz KM, Manikwar P, Joshi SB, Mcpherson CE, Buckland B, Srivastava IK, Middaugh CR, Volkin DB: Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage. J Pharm Sci 2014, 103:821-827.
22. Copeland CS, Zimmer KP, Wagner KR, Healey GA, Mellman I, Helenius A: Folding, trimerization, and transport are sequential events in the biogenesis of influenza virus hemagglutinin. Cell 1988, 53:197-209.
23. Gething MJ, Sambrook J: Protein folding and intracellular transport: studies on influenza virus haemagglutinin. Biochem Soc Symp 1989, 55:155-166.
24. Segal MS, Bye JM, Sambrook JF, Gething M-JH: Disulfide bond formation during the folding of influenza virus hemagglutinin. J Cell Biol 1992, 118:227-244.
25. Takeda M, Leser GP, Russell CJ, Lamb RA: Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc Natl Acad Sci U S A 2003, 100:14610-14617.
26. Jin H, Subbarao K, Bagai S, Leser GP, Murphy BR, Lamb RA: Palmitylation of the influenza virus hemagglutinin (H3) is not essential for virus assembly or infectivity. J Virol 1996, 70:1406-1414.
27. Zhang J, Pekosz A, Lamb RA: Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins. J Virol 2007, 4:4634-4644.
28. Chen BJ, Takeda M, Lamb RA: Influenza virus hemagglutinin (H3 subtype) requires palmitoylation of its cytoplasmic tail for assembly: M1 proteins of two subtypes differ in their ability to support assembly. J Virol 2005, 79:13673-13684.
29. Xu S, Zhou J, Liu K, Liu Q, Xue C, Li X, Zheng J, Luo D, Cao Y: Mutations of two transmembrane cysteines of hemagglutinin (HA) from influenza A H3N2 virus affect HA thermal stability and fusion activity. Virus Genes 2013, 47:20-26.
30. Zhou J, Xu S, Ma J, Lei W, Liu K, Liu Q, Ren Y, Xue C, Cao YC: Recombinant influenza A H3 N2 viruses with mutations of HA transmembrane cysteines exhibited altered virological characteristics. Virus Genes 2014, 8:273-282.
31. Xu S, Zhou J, Liu Q, Liu K, Xue C, Li X, Zheng J, Luo D, Cao YC: Evidences for the existence of intermolecular disulfide-bonded oligomers in the H3 hemagglutinins expressed in insect cells. Virus Genes 2014, 48:304-311.
32. Liu QL, Liu K, Xue CY, Zhou J, Li X, Luo D, Zheng J, Xu S, Liu GD, Cao YC: Recombinant influenza H1, H5, and H9 hemagglutinins containing replaced H3 hemagglutinin transmembrane domain showed enhanced heterosubtypic protection in mice. Vaccine 2014, 32:3041-3049.
33. Busconi L, Michel T: Recombinant endothelial nitric oxide synthase: post-translational modifications in a baculovirus expression system. Mol Pharmacol 1995, 47:655-659.
34. Reverey H, Veit M, Ponimaskin E, Schmidt MF: Differential fatty acid selection during biosynthetic S-acylation of a transmembrane protein (HEF) and other proteins in insect cells (Sf9) and in mammalian cells (CV1). J Biol Chem 1996, 271:23607-23610.
35. Böttcher C, Ludwig K, Herrmann A, van Heel M, Stark H: Structure of influenza haemagglutinin at neutral and at fusogenic pH by electron cryo-microscopy. FEBS Lett 1999, 463:255-259.
36. Ruigrok RWH, Wrigley NG, Calder LJ, Cusack S, Wharton SA, Brown EB, Skehel JJ: Electron microscopy of the low pH structure of influenza virus haemagglutinin. EMBO J 1986, 5:41-49.
37. Doms R, Helenius A: Quaternary structure of influenza virus hemagglutinin after acid treatment. J Virol 1986, 60:833-839.
38. Melikyan GB, Jin H, Lamb RA, Cohen FS: The role of the cytoplasmic tail region of influenza virus hemagglutinin in formation and growth of fusion pores. Virology 1997, 235(1):118-128.
39. Melikyan GB, White JM, Cohen FS: GPI-anchored influenza hemagglutinin induces hemifusion to both red blood cell and planar bilayer membranes. J Cell Biol 1995, 131:679-691.
40. Kemble GW, Henis YI, White JM: GPI-and transmembrane-anchored influenza hemagglutinin differ in structure and receptor binding activity. J Cell Biol 1993, 122:1253-1265.
41. Kemble GW, Danieli T, White JM: Lipid-anchored influenza hemagglutinin promotes hemifusion, not complete fusion. Cell 1994, 76:383-391.
42. Schroth-Diez B, Ludwig K, Baljinnyam B: The role of the transmembrane and of the intraviral domain of glycoproteins in membrane fusion of enveloped viruses. Bioscience 2000, 20:571-595.
43. Epand RM, Epand RF: Thermal denaturation of influenza virus and its relationship to membrane fusion. Biochemistry J 2002, 365:841-848.
44. Kordyukova LV, Serebryakova MV, Baratova LA, Veit M: S acylation of the hemagglutinin of influenza viruses: mass spectrometry reveals site-specific attachment of stearic acid to a transmembrane cysteine. J Virol 2008, 82:9288-9292.
45. Krogh A, Larsson B, von Heijne G, Sonnhammer EL: Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001, 305:567-580.
46. Sonnhammer EL, von Heijne G, Krogh A: A hidden Markov model for predicting transmembrane helices in protein sequences. Proc Int Conf Intell Syst Mol Biol 1998, 6:175-182.